About the Company
founded in 2015 by a team responsible for the fda's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, alpine immune sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. traded on nasdaq under ticker alpn.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ALPN News
Q4 2023 Alpine Immune Sciences Inc Earnings Call
Temre Johnson; Investor Relations and Corporate Communications; Alpine Immune Sciences Inc Mitchell Gold; Executive Chairman of the Board, Chief Executive Officer; Alpine Immune Sciences Inc Stanford ...
Alpine Immune Sciences Inc (ALPN) Reports Full Year 2023 Financial Results
Financial Position: Alpine ended 2023 with a strong cash position of $368.2 million, anticipating funding into 2026.
Alpine Immune Sciences, Inc. (ALPN) Q4 Earnings and Revenues Beat Estimates
Alpine Immune Sciences, Inc. (ALPN) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.32 per share. This compares to loss of $0.41 per share a ...
Buy Rating Affirmed for Alpine Immune Sciences Amidst Promising Clinical Trials and Forthcoming Data
TD Cowen analyst Tara Bancroft has maintained their bullish stance on ALPN stock, giving a Buy rating on March 12. Tara Bancroft has given his ...
Which Is a Better Investment, Alpine Immune Sciences Inc or SpringWorks Therapeutics Inc Stock?
Learn more about whether Alpine Immune Sciences Inc or SpringWorks Therapeutics Inc is a better investment based on AAII's A+ ...
Is a Surprise Coming for Alpine Immune Sciences (ALPN) This Earnings Season?
Investors are always looking for stocks that are poised to beat at earnings season and Alpine Immune Sciences, Inc. ALPN may ...
Recap: Alpine Immune Sciences Q4 Earnings
Alpine Immune Sciences beat estimated earnings by 144.0%, reporting an EPS of $0.15 versus an estimate of $-0.34. Revenue was up $28.08 million from the same period last year. Last quarter the company ...
Alpine Immune Sciences, Inc. (ALPN) Expected to Beat Earnings Estimates: Should You Buy?
Wall Street expects a year-over-year increase in earnings on higher revenues when Alpine Immune Sciences, Inc. (ALPN) reports results for the quarter ended December 2023. While this widely-known ...
Alpine Immune Sciences Inc 34LA
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Alpine Immune Sciences, Inc. (ALPN) Expected to Beat Earnings Estimates: Should You Buy?
Wall Street expects a year-over-year increase in earnings on higher revenues when Alpine Immune Sciences, Inc. (ALPN) reports results for the quarter ended December 2023. While this widely-known ...
Alpine Immune Sciences Inc.
Below is a summary of the major fundamental and technical factors we consider when determining our overall recommendation of ALPN shares. It is provided in order to give you a deeper understanding ...
Alpine Immune Sciences Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...